Weight-loss drug developers line up to tap market worth $150 billion
Updates with latest details on Pfizer, Roche and Carmot Therapeutics
July 17 (Reuters) -Novo Nordisk's NOVOb.CO Wegovy and Eli Lilly's LLY.N Zepbound are so far the leaders in the weight-loss drug market, which is estimated to be worth about $150 billion by the early 2030s.
But there are several other drug developers aiming to join the bandwagon. The following is a list of publicly listed companies targeting the next big blockbuster opportunity:
NOVO NORDISK
Novo's latest candidate, amycretin, helped obese patients achieve 13.1% weight loss after 12 weeks of treatment. The data compares to a weight loss of about 6% after 12 weeks in a trial for Wegovy.
Novo said it plans to begin a mid-stage study for amycretin in the second half of the year with results due in early 2026.
Novo Nordisk in August reported data from a large study, which showed Wegovy also had a clear cardiovascular benefit. Wegovy, which uses the same active ingredient as Novo's diabetes drug Ozempic, was approved in 2021.
The drugmaker in June reported late-stage trial data from a high-dose oral version of its drug, semaglutide, helping overweight or obese adults lose 15% of their body weight, which was in line with recent results for other experimental obesity pills.
The company said in February it will buy three of Catalent's fill-finish sites - in Anagni, Italy; Brussels, Belgium; and Bloomington, Indiana - from Novo Holdings for $11 billion to help boost its production of Wegovy. The sites will be acquired after Novo Holdings completes its Catalent acquisition.
ELI LILLY
Eli Lilly's weight-loss therapy, Zepbound, got the green light from U.S. and UK regulators in November, paving the way for a powerful new rival to Novo's Wegovy.
The company reported $175.8 million in sales of Zepbound in the first few weeks of its launch in December. The drug, chemically known as tirzepatide, has been available as Mounjaro for type 2 diabetes since 2022 and was used "off-label" for weight loss.
Lilly said in June a mid-stage trial of its next-generation obesity drug candidate, a once-weekly injection of retatrutide, led to a weight loss of up to 24.2% after 48 weeks.
PFIZER
Pfizer PFE.N said in December it was stopping further trials of a twice-daily version of its oral weight-loss drug, danuglipron.
The decision comes after most patients in a mid-stage trial dropped out with high rates of side effects such as nausea and vomiting.
In July, Pfizer said it planned to enter clinical trials later this year for a reworked, once-a-day version of its weight-loss pill, danuglipron.
ROCHE AND CARMOT THERAPEUTICS
Roche ROG.S acquired CT-388 as part of its $2.7 billion buyout of Carmot Therapeutics. Carmot's once-a-week injection belongs to the same class as Eli Lilly's LLY.N Mounjaro, or Zepbound.
In July, the companyannounced that a second drug candidate from its purchase of Carmot yielded positive results in an early-stage trial.
Roche said its experimental pill, which could appeal to patients averse to injections, was well tolerated with mostly mild or moderate gastrointestinal side effects similar to those seen in other weight-loss drugs.
AMGEN
Amgen's AMGN.O experimental obesity drug, AMG133, in November showed a mean weight loss of 14.5% after 12 weeks of treatment at the highest monthly dose.
ALTIMMUNE
Altimmune ALT.O in November said its drug candidate, pemvidutide, helped reduce weight by 15.6% on average and showed continued weight loss at the end of treatment in a mid-stage trial.
However, patients also experienced nausea and vomiting of mild and moderate severity.
VIKING THERAPEUTICS
Viking Therapeutics VKTX.O said in February its experimental drug, VK2735, helped patients with obesity achieve "significant" weight loss in a mid-stage study.
VK2735 helped patients achieve up to 14.7% mean weight loss after 13 weeks of treatment, according to data from the study, which had enrolled 176 overweight adults with at least one weight-related comorbidity.
ZEALAND PHARMA
Denmark's Zealand Pharma ZELA.CO and Boehringer Ingelheim's experimental obesity treatment achieved up to 14.9% weight loss in a mid-stage trial in May.
OPKO HEALTH
Opko Health OPK.O has completed a mid-stage trial of its obesity drug, pegapamodutide, which it expects will have fewer side effects.
STRUCTURE THERAPEUTICS
Structure Therapeutics GPCR.O said its experimental oral obesity drug helped reduce weight by 6.2% on average at the end of 12 weeks in a mid-stage study.
Weight-loss drug forecasts jump to $150 billion as supply grows https://www.reuters.com/business/healthcare-pharmaceuticals/weight-loss-drug-forecasts-jump-150-billion-supply-grows-2024-05-28/
Reporting by Mariam Sunny, Pratik Jain, Sriparna Roy, Leroy Leo, Sneha S K and Nathan Gomes in Bengaluru; Editing by Sriraj Kalluvila, Pooja Desai, Maju Samuel and Tasim Zahid
Relaterade tillgångar
Senaste nytt
Ansvarsfriskrivning: XM Group-enheter tillhandahåller sin tjänst enbart för exekvering och tillgången till vår onlinehandelsplattform, som innebär att en person kan se och/eller använda tillgängligt innehåll på eller via webbplatsen, påverkar eller utökar inte detta, vilket inte heller varit avsikten. Denna tillgång och användning omfattas alltid av i) villkor, ii) riskvarningar och iii) fullständig ansvarsfriskrivning. Detta innehåll tillhandahålls därför uteslutande som allmän information. Var framför allt medveten om att innehållet på vår onlinehandelsplattform varken utgör en uppmaning eller ett erbjudande om att ingå några transaktioner på de finansiella marknaderna. Handel på alla finansiella marknader involverar en betydande risk för ditt kapital.
Allt material som publiceras på denna sida är enbart avsett för utbildnings- eller informationssyften och innehåller inte – och ska inte heller anses innehålla – rådgivning och rekommendationer om finansiella frågor, investeringsskatt eller handel, dokumentation av våra handelskurser eller ett erbjudande om, eller en uppmaning till, en transaktion i finansiella instrument eller oönskade finansiella erbjudanden som är riktade till dig.
Tredjepartsinnehåll, liksom innehåll framtaget av XM såsom synpunkter, nyheter, forskningsrön, analyser, kurser, andra uppgifter eller länkar till tredjepartssajter som återfinns på denna webbplats, tillhandahålls i befintligt skick, som allmän marknadskommentar, och utgör ingen investeringsrådgivning. I den mån som något innehåll tolkas som investeringsforskning måste det noteras och accepteras att innehållet varken har varit avsett som oberoende investeringsforskning eller har utarbetats i enlighet med de rättsliga kraven för att främja ett sådant syfte, och därför är att betrakta som marknadskommunikation enligt tillämpliga lagar och föreskrifter. Se till så att du har läst och förstått vårt meddelande om icke-oberoende investeringsforskning och riskvarning om ovannämnda information, som finns här.
